Equities

YiChang HEC ChangJiang Pharmaceutical Co Ltd

YiChang HEC ChangJiang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)9.00
  • Today's Change-0.03 / -0.33%
  • Shares traded1.64m
  • 1 Year change+8.17%
  • Beta0.8857
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,6931,2141,131
Total Receivables, Net2,1131,037547
Total Inventory409315280
Prepaid expenses271597.78
Other current assets, total1,5672,38992
Total current assets6,0535,0142,057
Property, plant & equipment, net3,8503,7053,281
Goodwill, net--076
Intangibles, net2,5662,9213,272
Long term investments3201,790
Note receivable - long term------
Other long term assets------
Total assets12,74411,89010,542
LIABILITIES
Accounts payable200167115
Accrued expenses1,3971,340140
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,3203,13048
Other current liabilities, total415304934
Total current liabilities4,3324,9411,238
Total long term debt2896923,145
Total debt2,6093,8223,194
Deferred income tax------
Minority interest0185212
Other liabilities, total187187138
Total liabilities4,8096,0054,733
SHAREHOLDERS EQUITY
Common stock880880880
Additional paid-in capital------
Retained earnings (accumulated deficit)7,0565,0054,928
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity7,9365,8855,808
Total liabilities & shareholders' equity12,74411,89010,542
Total common shares outstanding880880880
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.